Several studies emphasise that arabinoxylan and b-glucan have more beneficial effects on glucose metabolism than low-dietary fibre (DF) meals. Less attention has been paid to the effects of concentrated DF compared with whole grain. We compared the effects of DF and whole grain on glucose, hormone responses and appetite in subjects with the metabolic syndrome (MetS). SUBJECTS/METHODS: Fifteen subjects with MetS participated in this acute, randomised, cross-over intervention study. The test breads provided 50 g of digestible carbohydrate: wheat bread with concentrated arabinoxylan (AX) or b-glucan (BG), rye bread with kernels (RK) and wheat bread (WB) as control. Blood samples were drawn for 270 min to determine glucose, insulin, glucagon-like peptide-1, glucose-dependent insulinotropic peptide (GIP) and ghrelin. Appetite score was addressed every 30 min. Ad libitum energy intake (EI) was measured 270 min after test meals. RESULTS: Compared with WB, BG and RK induced lower initial glycaemic responses (Po0.001), whereas AX only reduced the glucose peak value (Po0.001). RK reduced insulin (Po0.001) and GIP responses (Po0.001) compared with the other breads. BG lowered insulin responses more than AX (Po0.001). AX, BG and RK increased satiety feeling (Po0.001) more than WB, but did not differ significantly in terms of subsequent EI (P ¼ 0.089). CONCLUSION: BG and RK had beneficial impact on the glucose response, whereas AX had only effect on the postprandial glucose peak. The impact of the AX bread was influenced by higher protein content. Whether the metabolic effects of the breads are still present to mixed meals remains to be tested.
INTRODUCTION
The prevalence of the metabolic syndrome (MetS) and type 2 diabetes (T2D) is rapidly increasing globally, which calls for urgent preventive lifestyle interventions. Prospective studies have shown an inverse relationship between the intake of whole grain and the risk of T2D and weight gain. [1] [2] [3] Whole grain products are characterised by a higher content of dietary fibre (DF) and other bioactive, nutritionally beneficial compounds than refined products. DF may contribute to these preventive effects by increasing the viscosity, 4 delaying gastric emptying 5 and thereby potentially slowing glucose absorption. 6 A lower energy density combined with prolonged secretion of appetite-regulating hormones may also have an important role. 7 The predominant DF in wheat and rye is arabinoxylan, which is a diversely composed xylose polymer coupled with arabinose and, depending on the source, varying content of uronic acid residues. 8 Mixed linked (1-3)(1-4)-b-glucan (b-glucan) is found primarily in the endosperm and subaleurone cell walls of oat and barley. In whole grain products, arabinoxylan and b-glucan are present in soluble and insoluble forms, but the soluble form of both DF polymers can be concentrated by various means. 9, 10 Most human studies have shown that arabinoxylan [10] [11] [12] and b-glucan 13, 14 reduce glucose and insulin responses more than low-DF products. Recently, we also demonstrated a beneficial effect of arabinoxylan on glucose and insulin in animals. 15 However, results on ghrelin responses 10, 16 and the link between arabinoxylan and b-glucan with respect to satiety and satiation [17] [18] [19] are conflicting. Moreover, the presence of intact kernels may provide an additional means with which to influence glycaemia because physically they slow the rate of starch hydrolysis in the gut.
Most studies of isolated and concentrated DF are conducted in subjects who are healthy or suffer from T2D. These studies compare the effect of isolated and concentrated DF with refined wheat products (negative control). Only few have compared the effect of isolated DF with whole grain products (positive control) at same DF levels. We hypothesised that high-DF breads have beneficial effects on the glucose responses and promote a satiety feeling in subjects with MetS. We tested this hypothesis by evaluating the acute effects of four bread types on glucose, insulin and incretin responses as well as on appetite regulation in subjects with MetS. We compared three high-DF breads, that is, two refined wheat breads supplemented with concentrates of oat b-glucan (BG bread) or wheat arabinoxylan (AX bread), and rye bread with intact kernels (RK bread) (positive control). These three breads were compared with refined wheat bread (WB) (negative control). The design allowed a comparison of breads with concentrated DF with whole grain as well as with WB.
SUBJECTS AND METHODS Subjects
Fifteen Caucasian subjects (seven men and eight postmenopausal women) with MetS according to the definition of The International Diabetes Federation 20 were recruited by the study coordinator from August to December 2011 by advertising in local newspapers. All subjects were nonsmokers and non-diabetic as determined by fasting glucose levels o7.0 mmol/l and HbA1co6.5%. Nine subjects were treated with blood pressure-lowering medication and seven with cholesterol-lowering medication. No change in concomitant medication was allowed during the trial. Subject characteristics are shown in Table 1 . All subjects gave their written informed consent to participate in the study and the Central Denmark Region Committees on Health Research Ethics approved the study according to the Helsinki Declaration. The study was registered at Clinicaltrials.gov ID: NCT01316354.
Design
The study was designed as an acute, randomized cross-over study with four test breads provided in random order with an in-between washout of B1 week. The subjects were randomly assigned to the sequence of the test breads by the study coordinator by use of a Latin-Square design. To conceal the sequence until interventions were assigned, the sequence for each subject was kept in a closed numbered envelope. Subjects were given a standard low-DF diet to be consumed the day before each study day. The diet contained 50% of energy as carbohydrate (16 g DF per day), 30% of energy as fat and 20% of energy as protein with an energy content equivalent to the subjects' estimated energy requirement. They were instructed not to drink alcohol or perform strenuous exercise the day before each study day, nor to take any medication on the study day, and to maintain their regular lifestyle throughout the entire study. After 20 00 hours on the preceding day, they were allowed to drink 500 ml of tap water. After a 12-h fasting period, subjects arrived at the laboratory (Aarhus University Hospital, Aarhus, Denmark) at 07 30 hours after a minimum of physical activity, were weighed (Tanita WB-100A, Tokyo, Japan) and filled in the first visual analogue scale (VAS). After 15 min of rest, a catheter was inserted into an antecubital vein and baseline samples were drawn. Bread corresponding to 50 g digestible carbohydrate was served with 300 ml of tap water and ingested within 15 min. After 120 min, another 200 ml of tap water was served. Blood samples were drawn at 0, 15, 30, 45, 60, 90, 120, 180, 240 and 270 min. In-between these intervals, the subjects rested at the clinic. Appetite sensation was assessed every 30 min during the entire study period. After 270 min, an ad libitum meal consisting of pizza with tomato sauce, ham and cheese (Easyfoods A/S, Kolding, Denmark) was served together with 300 ml of tap water and the energy intake was calculated. The pizza was heated at 230 1C for 10 min and cut into differently sized slices. The energy content (953 kJ/100 g) was obtained from the manufacturer and the same batch was used throughout the study. Subjects were instructed to eat the amount needed to reach comfortable satiation. The next test day, they were instructed to eat until the same degree of satiation.
Appetite sensations VAS was used to assess hunger, satiety, fullness and prospective consumption of the test breads. 21 VAS consist of a 100 mm line scale with words anchored at each end, expressing the most positive and the most negative rating. The questionnaires were made as small booklets showing one question at a time. Subjects were not allowed to discuss ratings.
Test breads
The concentrated wheat arabinoxylan-fraction (Manildra Group, Nowra, NSW, Australia) consisted on dry matter basis of 46.4% non-digestible carbohydrates (NDC), 31.2% non-starch polysaccharides (NSP), 23.4% arabinoxylan with an arabinose-to-xylose ratio of 0.9, a protein content of 39.7% and a weight average molecular weight (M w ) of 602 kDa. 22 Soluble b-glucan (PromOat) was obtained from BioVelop AB, Kimstad, Sweden. It contained 46.8% NDC, 40.5% NSP, 35.2% b-glucan of which 34.6% was soluble, 4.3% protein and had a M w of 1978 kDa. 22 The dry ingredients of the AX bread were: 67.8% refined wheat flour, 24.4% arabinoxylan concentrate, 0.9% sugar, 1.7% salt, 1.8% margarine (80% vegetable fat) and 3.5% yeast. The BG bread was made with: 71.0% refined wheat flour, 13.3% PromOat, 6.9% Vitacel WF600 (J Rettenmaier & Sö hne GmbH, Rosenberg, Germany), 1.0% wheat gluten, 0.9% sugar, 1.7% salt, 1.8% margarine (80% vegetable fat) and 3.5% yeast. Vitacel WF600, a refined commercial fibre product produced from wheat straw, consists of 72.7% cellulose and 16.9% of arabinoxylan with an arabinose-to-xylose ratio of 0.09. Vitacel WF600 was added to achieve a DF level comparable with the other high-DF breads. The dough of the AX and BG bread were proved 30 min at 30 1C with steam and baked for 40 min at 160 1C (hot air and steam) at the canteen at Aarhus University, Tjele, Denmark. The RK and the WB bread were commercial products produced by Lantmännen Food R&D, Schulstad (Hvidovre, Denmark) under the commercial names of Multikernerugbrød and Hvede toast, respectively. The ingredients for the RK bread were: rye kernels (49%), water, rye sourdough, rye bread crumbs, wheat meal, salt, yeast, vinegar, dried sourdough rye, canola oil, rye and barley flour. The WB bread was baked using wheat flour (68%), water, yeast, sugar, salt, vinegar, canola oil, emulsifier (E471, E472e), rye flour, barley malt flour and flour treatment agent (ascorbic acid). All breads were sliced, put into plastic bags and stored at À 20 1C. On the day before the experiment, the breads were thawed at room temperature. The composition of the test breads is shown in Table 2 .
Chemical analysis
Analyses of the breads were performed in duplicate on freeze-dried materials. Nitrogen (protein: N Â 6.25) was measured by DUMAS 23 and fat according to the Stoldt procedure. 24 Starch and NSP were analysed as described by Bach Knudsen 25 and Klason lignin was analysed as previously described. 26 b-glucan was determined by the AOAC method 995.16 using a Megazyme kit (Megazyme International Ireland Ltd., Wicklow, Ireland). Low molecular weight NDC were calculated as: (total carbohydrates À NSP À starch). Total carbohydrates were analysed as NSP without prior starch removal. Resistant starch was calculated as: (NSP glucose À (cellulose þ b-glucan)). Digestible carbohydrates were the sum of sugars and starch.
Blood samples
Immediately after the blood samples were drawn, plasma was separated by centrifugation at 2000 Â g for 15 min at 4 1C and stored at À 80 1C. Plasma glucose was measured by a glucose oxidase method (GOD-PAP glucose kit, Cat. no. 11491253 216, Roche Diagnostics Gmbh, Mannheim, Germany). Plasma insulin was measured with ELISA using a DAKO insulin kit (Code K6219; Dako, Glostrup, Denmark). Total glucagon-like peptide-1 (GLP-1) was measured using a radioimmunnoassay (antiserum no. 89390) specific for the C-terminal of the GLP-1 molecule as previously described. 27 Glucose-dependent insulinotropic peptide (GIP) was measured using a C-terminally directed antiserum. 28 Both incretin assays were carried out after extraction of plasma with 70% ethanol (vol/vol, final concentration). 
Statistical analysis
The power calculation was based on our primary effect parameter glucose incremental area under the curve (iAUC). The number of participants needed to obtain a statistical power of 80% at a level of Po0.05 (a ¼ 0.05; 1 À b ¼ 0.8) was calculated as 12. We wanted to detect a minimal relevant difference for the area of (mean±s.d.) 65±50 mmol/l Â 120 min, which gives us an estimated effect size of 1.30. The anticipated dropout was set to 20%. Descriptive statistics are presented as mean ± s.d. and results as mean ± s.e.m. from all 15 participants. Statistical analyses were performed using STATA/IC 11.2. The iAUC for glucose, insulin, GLP-1 and GIP was calculated using the trapezoid model. The AUC was calculated for VAS and ghrelin. The glycaemic index (GI) and the insulinaemic index (II) were calculated as iAUC120 min for glucose and insulin, respectively, after ingestion of AX, RK and BG breads relative to that after ingestion of WB. Cumulative ad libitum food intake was calculated as the amount of bread consumed at breakfast plus the pizza ad libitum meal. ANOVA for repeated measurements was used to examine the effect of bread and time on the postprandial responses and appetite sensation using subject and day as random variables; baseline, body mass index, age and waist as covariates and gender as systematic variables. Model validation was performed by inspecting the probability plot of the residuals. Significant differences between test breads at individual time points were assessed only if a significant time Â treatment interaction was found. For iAUC, AUC and peak values, the statistical analysis was performed using ANOVA. Whenever data were not normally distributed, a log transformation was performed and data are presented as geometric mean with 95% CI. A P-valueo0.05 was considered significant and followed up by a post hoc Bonferroni correction.
RESULTS
All 15 subjects completed the four test days according to the protocol. No significant differences in fasting concentrations of the measured variables and no significant weight changes between the first (93.2±14.6 kg) and the last (93.6±14.8 kg) test day were observed.
Glucose Glucose iAUC120 min was significantly lower after BG (P ¼ 0.001) and RK (Po0.001) consumption than after WB ( Figure 1a , Table 3) . GI values were significantly lower for BG bread (84±6%; P ¼ 0.006) and RK bread (77±5%; Po0.001) than for WB (GI ¼ 100%; Table 4 ). Glucose peak values were significantly lower for AX bread (P ¼ 0.001), BG bread (Po0.001) and RK bread (Po0.001) than for WB ( Figure 1a , Table 4 ).
Insulin
Insulin iAUC120 min was significantly higher after AX (121%; Po0.001), WB (97%; Po0.001) and BG bread (65%; Po0.001) than after RK bread (Figure 1b , Table 3 ). In addition, insulin iAUC120 min was significantly higher for AX bread (34%; P ¼ 0.001) than for BG bread. The same was observed when expressed as II (Table 4 ).
Incretins GLP-1 peak values ( (Figure 1c ). RK bread ingestion lowered the GIP iAUC120 min compared with the other kinds of bread ( Figure 1d , Table 3 ). In addition, the GIP iAUC120 min for BG bread was lower than for WB (P ¼ 0.003) ( Table 3) .
Ghrelin
Ghrelin AUC120 min and AUC270 min were overall different between the four groups ( Figure 1d , Table 3 ). In post hoc analysis ghrelin AUC was significantly lower for AX than for RK bread (AUC120 min; P ¼ 0.005 and AUC270 min; P ¼ 0.005). There were no significant differences in ghrelin levels between bread types in the late postprandial period (AUC120-270 min).
Appetite sensation and lunch intake AUC for satiety was significantly higher for AX (12 875 ± 609 mm Â 270 min; Po0.001), BG (12 280±825 mm Â 270 min; P ¼ 0.001) and RK bread (12 737 ± 635 mm Â 270 min; Po0.001) than for WB (9532 ± 754 mm Â 270 min). AUC for hunger was significantly lower for AX (Po0.001), BG (P ¼ 0.004) and RK bread (P ¼ 0.004) than for WB ( Figure 2 , Table 3 ). AX (Po0.001) and RK bread (P ¼ 0.002) resulted in significantly higher AUC for fullness than WB. AUC for prospective consumption was significantly lower for AX (Po0.001), BG (P ¼ 0.004) and RK bread (P ¼ 0.004) than for WB (Table 4) . There was no effect of the bread types (Table 4) on ad libitum food intake (P ¼ 0.089) or cumulative ad libitum food intake (P ¼ 0.071).
DISCUSSION
We investigated two experimental high-DF breads with concentrated arabinoxylan and b-glucan and compared them with a low-DF WB as negative control and a high-DF rye bread with intact kernels as positive control in terms of postprandial glucose and hormone responses and appetite regulation in subjects with MetS. In the present investigation, the AX bread containing 7 g of arabinoxylan did not reduce the GI significantly compared with WB. This result corroborates a previous study of bread with 6 g of concentrated arabinoxylan. 16 In contrast, Lu et al. 11 found a lower GI for bread containing both 6 and 12 g concentrated arabinoxylan than for a control white wheat bread. The controversy may be explained by differences in the chemical composition of the tested concentrated arabinoxylan or differences in study populations. Interestingly, we did not find a low insulin response to the AX bread despite a lower glucose peak value than for the control meal. This may be ascribed to the high protein content in the AX bread. Thus, 40% of dry matter in the arabinoxylan concentrate is protein, which is known to exert insulinotropic effects. 29 Studies examining arabinoxylan with a lower level of protein found Abbreviations: AX, arabinoxylan bread; iAUC, incremental area under the curve; BG, b-glucan bread; CI, confidence interval; GIP, glucose-dependent insulinotropic peptide; GLP-1, glucagon-like peptide-1; RK, rye bread with kernels; WB, wheat bread. Fibre, glucose, appetite and metabolic syndromereduced insulin responses compared with white bread. 11, 16 However, in subjects with normal fasting glucose and glucose tolerance, the insulin response was not reduced. 16 Our finding in the present study of an average GI of 77 for RK bread is in accordance with our previous findings 30 and may be explained by the reduced glycaemic response due to protection of starch hydrolysis by the intact kernels. 31 Rye has in other studies been shown to elicit low insulin responses 32, 33 independently of the DF level and the glucose response 33 results corroborating our findings. Intact kernels 34 and a firmer structure of rye may have an important role and explain this observation. 32, 33 Our BG bread, which contained 4.2 g b-glucan (4.1 g soluble), induced a significantly lower GI than WB. This is in concert with a study with oat muesli where a dose of 4 g b-glucan per meal 35 reduced postprandial glucose levels in healthy subjects. An increased intestinal viscosity resulting in reduced rate of absorption and subsequent glucose response is the most likely reason for this reduction as also demonstrated in liquid meals supplemented with isolated oat b-glucan. 4 Both the amount and molecular weight of soluble b-glucan are reported to have a critical role for this effect. 4, 36 It is therefore puzzling that the insulin responses to WB and BG bread did not differ significantly, but this is probably due to the large variations in insulin responses in our subjects with MetS. In contrast, in healthy subjects a reduced postprandial insulin response was found after a oat bran meal containing 4 g b-glucan compared with white bread. 35 In overweight subjects, 3.8 g b-glucan per meal from oat bran and 5.7 g b-glucan concentrate have also been observed to reduce insulin responses in the first 2 h postprandially compared with a control meal. 37 The GIP response was lower after RK bread than after WB, BG and AX bread. The same pattern was seen for insulin, which indicates that this hormone may regulate postprandial insulin as also found by Juntunen et al. 34 In addition they showed that the GLP-1 response did not differ between bread with b-glucan and white bread 34 in line with our findings. In contrast, others have found that the GLP-1 response may be influenced by the viscosity of b-glucan-rich oat bran, that is, a reduction in viscosity induces a higher nutrient-mediated GLP-1 response. 19 A higher peak value of GLP-1 after the AX bread was combined with a higher insulin response, which may be related to the high protein content of the bread. 38 Studies with concentrated arabinoxylan have shown both increased 16 and decreased 10 levels of total ghrelin compared Fibre, glucose, appetite and metabolic syndrome ML Hartvigsen et al with white bread. We observed no differences in ghrelin between WB and AX bread, but found a lower initial AUC of ghrelin following AX bread ingestion than after RK bread. This supports previous findings, 39, 40 which indicate that insulin may suppress ghrelin release, possibly mediated via GLP-1. The ghrelin responses did not differ between WB and BG bread. This is in line with previous findings regarding b-glucan from oat bran and oat b-glucan concentrate 37 but in contrast to results on barley b-glucan concentrate. 41 Thus, differences in botanical structure but also the provided level of DF and the tested food matrix may have an important role for ghrelin responses. Neither did the ghrelin responses differ between WB and RK bread, as previously observed. 32, 42 All three high-DF breads induced higher satiety feeling than WB. The high protein content and higher energy content of the AX bread may have contributed to the satiety feeling. 38 Furthermore, higher initial GLP-1 responses to the AX bread may have inhibited gastric emptying, lowered peak glucose and increased satiety feeling. A larger volume 43 or effects of bioactive compounds present in whole grain may have contributed to the higher satiety sensation after the RK bread than after WB. An increased satiety feeling from the BG bread agrees with previous studies, which show that viscous fibre increases short-term satiety more than non-viscous fibre. 44 However, in our study this is not related to a rise in GLP-1 levels. The GI results did not fit with our satiety scores for all breads, and other factors like the volume of the meal and the physiochemical properties of the fibres may be more important to satiety.
It is noteworthy that all three high-DF breads increased the satiety feeling, apparently unrelated to the ghrelin response and with no significant effect on the following ad libitum lunch intake. If the lunch meal had been served earlier, for example, after 3 h we cannot exclude to have picked up a significant difference in ad libitum intake as previously observed. 41 It should be added that differences in ad libitum intake were seen to white bread compared with rye after 4½ h. 42 A limitation of the present study was that the VAS and ad libitum meal were not among our primary effect variables in the power calculation. Therefore, we cannot exclude that our inability to detect a significant difference in ad libitum food intake between the breads represents a type 2 error. 21, 45 In the present study, the effects of the AX bread may in part be related to the high protein and energy content. The high insulin response to the AX bread may be disadvantageous as excessive beta-cell stimulation could impair beta-cell function in the long term. Therefore, more efforts are needed to improve the composition of the concentrated arabinoxylan to balance the effect between glucose and insulin. However, breads with high levels of both protein and DF may possess a beneficial potential as part of a healthy diet for subjects with MetS. In the present study we have chosen to explore the test breads alone, which clearly does not reflect a normal diet. Consequently, the possible effect of the tested breads within a mixed meal needs to be demonstrated to clarify the importance of our findings.
In conclusion, our study supports the hypothesis that high-DF breads promote satiety feeling in subjects with MetS. Concentrated b-glucan and rye whole grain have beneficial effect on the postprandial glucose response, whereas concentrated arabinoxylan only had a minor effect on the glucose response. Rye whole grain has particular beneficial effects regarding the balance between circulating glucose and insulin levels. Further attempts to compare potential benefits of concentrated DF are needed, for example, to clarify the effective dose and composition, to explore a potential second meal effect and in long-term studies to elucidate if these concentrated DF have consequences for body weight.
